identifying a patient suffering from a disease selected from the group consisting of cancer, autoimmune disease, and infection; administering to said patient adoptive cellular therapy ACT comprising either a cell used to enhance the immune system in treating said cancer or a cell derived from an immune lineage which directly treats said cancer; and administering a non toxic lymphodepleting agent NTLA, which lymphodepletes and ablates the secondary lymphatic binding sites where said cellular immunotherapy binds and accumulates, and is selected from the group consisting of Tacrolimus delivered as an injection or oral dose of 0 best place to buy cialis online Jarvinen J, Kullaa Mikkonen A, Kotilainen R